Kamboj Sunjeev K, Tookman Adrian, Jones Louise, Curran Valerie H
Clinical Psychopharmacology Unit, Sub-Department of Clinical Health Psychology, University College London, Gower Street, London, WC1E 6BT, UK Edenhall, Marie Curie Centre, Royal Free Hospital Trust, London, UK.
Pain. 2005 Oct;117(3):388-395. doi: 10.1016/j.pain.2005.06.022.
Morphine and other potent opioids are frequently used in palliative care and pain management. When sustained-release (SR) opioids do not provide adequate background analgesia, additional immediate-release (IR) opioid (e.g. short-acting morphine) may be required to alleviate breakthrough or episodic pain. Despite the frequent use of IR morphine on top of SR opioids, little is known about the effects of such treatment on patients' everyday cognitive functioning. This study therefore used a double-blind, placebo-controlled, cross-over design to assess cognitive functioning in 14 patients receiving palliative care. All patients were taking SR opioid preparations and required <or=2 doses of IR morphine/day. Performance on cognitive measures (as well as subjective measures of pain and mood) after a dose of IR morphine was compared with placebo. Patients experienced significantly more pain-reduction following IR morphine (P=0.03), while other measures of subjective drug effects (e.g. sedation) were largely unaffected. Patients displayed anterograde memory impairment after IR morphine relative to placebo (P=0.003). Intriguingly, patients also had significant 'retrograde' memory impairment: delayed recall of verbal information presented before IR morphine also declined (P=0.024). In addition, IR morphine reduced performance on a complex tracking task (Reitan's trails B; P=0.03) whilst enhancing it on a simpler tracking task (Reitan's trails A; P=0.03). In conclusion, this study suggests that IR morphine, when taken on top of a SR opioid, produces transient anterograde and retrograde memory impairments and a decrement in two-target tracking. These impairments may impact negatively on patients' everyday functioning.
吗啡和其他强效阿片类药物常用于姑息治疗和疼痛管理。当缓释(SR)阿片类药物不能提供足够的背景镇痛效果时,可能需要额外使用即释(IR)阿片类药物(如短效吗啡)来缓解爆发性或间歇性疼痛。尽管常在SR阿片类药物基础上加用IR吗啡,但对于这种治疗对患者日常认知功能的影响却知之甚少。因此,本研究采用双盲、安慰剂对照、交叉设计,对14例接受姑息治疗的患者的认知功能进行评估。所有患者均服用SR阿片类制剂,且每天需要≤2剂IR吗啡。将一剂IR吗啡后的认知测量表现(以及疼痛和情绪的主观测量)与安慰剂进行比较。IR吗啡治疗后患者疼痛缓解明显更多(P = 0.03),而其他主观药物效应测量指标(如镇静)基本未受影响。与安慰剂相比,IR吗啡治疗后患者出现顺行性记忆损害(P = 0.003)。有趣的是,患者还存在明显的“逆行性”记忆损害:对IR吗啡给药前呈现的言语信息的延迟回忆也下降了(P = 0.024)。此外,IR吗啡降低了复杂追踪任务(雷顿氏B型连线测验;P = 0.03)的表现,而在较简单的追踪任务(雷顿氏A型连线测验;P = 0.03)中表现增强。总之,本研究表明,在SR阿片类药物基础上加用IR吗啡会产生短暂的顺行性和逆行性记忆损害以及双目标追踪能力下降。这些损害可能会对患者的日常功能产生负面影响。